Karyopharm Q2 net loss $37.3M; explores financing/strategic alternatives; cash $52M

Karyopharm Therapeutics Inc.

2025-Q2 EPS reported -$7.11 vs consensus -$4.18 ▼ miss (-70.1%)

Total revenue $37.9M; US XPOVIO net product revenue $29.7M (+6% YoY). Net loss $37.3M ($4.32/share).
FY2025 total revenue guidance reaffirmed $140-155M; US XPOVIO revenue guidance updated to $110-120M.
Cash, equivalents & investments $52M at June 30; expects liquidity to fund ops into Jan 2026 excluding $24.5M note maturity Oct 2025.
Phase 3 SENTRY (myelofibrosis) enrollment screening close this week; top-line data expected March 2026.
Engaged Centerview Partners to explore financing and strategic alternatives to extend cash runway and maximize value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.